ArticleCureus2025
Assessing Brain Neurophysiology in COVID-19 Patients With Prolonged Cognitive Fatigue: A Comparison With Persistent Post-concussion Symptoms.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionBrain fog and cognitive dysfunction are frequently reported in post-viral fatigue syndromes such as long COVID, yet these symptoms remain challenging to quantify objectively. Notably, many individuals with long COVID describe clinical features that overlap with those observed in patients with persistent post-concussion symptoms (PPCS), including cognitive fatigue, exertional intolerance, mood disturbances, visual and balance problems, headaches, and neck pain. Emerging evidence suggests that PPCS is associated with distinct electrophysiological abnormalities, including altered functional connectivity (measured by electroencephalography (EEG) coherence), spatial changes in EEG amplitude distribution (notably increased frontal alpha and left-right asymmetry), and reduced cognitive evoked potentials (e.g., the auditory P300 response). In this study, we investigated whether these electrophysiological markers of PPCS are also present in individuals experiencing post-viral fatigue following COVID-19, aiming to provide objective measures to better characterize and quantify cognitive impairment in this population. MATERIALS AND
methodsThirty-one patients (mean age 45 ± 9 years) reporting persistent neurocognitive symptoms following COVID-19 infection (10 ± 2 months post-infection) were evaluated at intake to a brain injury clinic while seeking assessment/treatment for prolonged cognitive complaints. Over this time period, 64 PPCS patients (69% female; age: 42 ± 11 years) were evaluated at the same clinic for concussion-related symptoms using identical protocols. These were compared to seventy age-matched controls (mean age 45 ± 5 years) without a history of COVID-19 or neurological conditions. Assessments comprised standard concussion assessments with symptom profiles that included cognitive fatigue and EEG with event-related potentials (ERP). We then compared the EEG and ERP metrics known to be sensitive to declines in mental performance (i.e., PPCS) for both the long COVID group and age-matched controls.
resultsThe long COVID cohort demonstrated neurophysiological alterations paralleling those observed in PPCS, including significantly impaired processing speed and reduced physical reaction times compared to controls (p < 0.001), as well as cognitive electrophysiological deficits, such as attenuated P300 amplitudes, which reflect impaired attention allocation (p < 0.001). These biomarkers normalized concomitantly with symptom resolution at long-term follow-up (mean 20 ± 8 months post-baseline assessment).
conclusionsOur data demonstrate that ERP deficits, characteristic of cognitive decline in conditions like concussion, PPCS, and aging, are replicable in long COVID patients. Notably, these electrophysiological abnormalities (reduced P300 amplitude and altered coherence) correlate with quantifiable cognitive fatigue and functional neurological impairments. Biomarker normalization tracked with symptom resolution at follow-up (20 ± 8 months), confirming their clinical relevance. These accessible metrics provide objective parameters to identify virally induced cognitive deficits, addressing a critical need for validated diagnostic tools in post-viral syndromes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.